Braaten Douglas C, Sparks-Thissen Rebecca L, Kreher Scott, Speck Samuel H, Virgin Herbert W
Department of Pathology and Immunology, Washington University School of Medicine, 660 S. Euclid, Box 8118, St. Louis, MO 63110, USA.
J Virol. 2005 Feb;79(4):2573-83. doi: 10.1128/JVI.79.4.2573-2583.2005.
Strategies to prime CD8(+) T cells against Murine gammaherpesvirus 68 (gammaHV68; MHV68) latency have, to date, resulted in only limited effects. While early forms of latency (<21 days) were significantly reduced, effects were not seen at later times, indicating loss of control by the primed CD8(+) T cells. In the present study, we evaluated CD8(+) T cells in an optimized system, consisting of OTI T-cell-receptor (TCR) transgenic mice, which generate clonal CD8(+) T cells specific for K(b)-SIINFEKL of OVA, and a recombinant gammaHV68 that expresses OVA (gammaHV68.OVA). Our aim was to test whether this optimized system would result in more effective control not only of acute infection but also of later forms of latent infection than was seen with previous strategies. First, we show that OTI CD8(+) T cells effectively controlled acute replication of gammaHV68.OVA in liver, lung, and spleen at 8 and 16 days after infection of OTI/RAG mice, which lack expression of B and CD4(+) T cells. However, we found that, despite eliminating detectable acute replication, the OTI CD8(+) T cells did not prevent the establishment of latency in the OTI/RAG mice. We next evaluated the effectiveness of OTI T cells in OTI/B6 animals, which express B cells--a major site of latency in wild-type mice--and CD4(+) T cells. In OTI/B6 mice OTI CD8(+) T cells not only reduced the frequency of cells that reactivate from latency and the frequency of cells bearing the viral genome at 16 days after infection (similar to what has been reported before) but also were effective at reducing latency at 42 days after infection. Together, these data show that CD8(+) T cells are sufficient, in the absence of B cells and CD4(+) T cells, for effective control of acute replication. The data also demonstrate for the first time that a strong CD8(+) T-cell response can limit long-term latent infection.
迄今为止,针对小鼠γ疱疹病毒68(γHV68;MHV68)潜伏期激发CD8(+) T细胞的策略仅产生了有限的效果。虽然早期潜伏期形式(<21天)显著减少,但后期未观察到效果,这表明激发的CD8(+) T细胞失去了控制能力。在本研究中,我们在一个优化系统中评估了CD8(+) T细胞,该系统由OTI T细胞受体(TCR)转基因小鼠组成,这些小鼠产生针对OVA的K(b)-SIINFEKL的克隆性CD8(+) T细胞,以及表达OVA的重组γHV68(γHV68.OVA)。我们的目的是测试这个优化系统是否不仅能比以前的策略更有效地控制急性感染,还能控制后期的潜伏感染形式。首先,我们表明,在缺乏B细胞和CD4(+) T细胞表达的OTI/RAG小鼠感染后8天和16天,OTI CD8(+) T细胞有效地控制了γHV68.OVA在肝脏、肺和脾脏中的急性复制。然而,我们发现,尽管消除了可检测到的急性复制,但OTI CD8(+) T细胞并不能阻止OTI/RAG小鼠中潜伏期的建立。接下来,我们评估了OTI T细胞在OTI/B6动物中的有效性,这些动物表达B细胞(野生型小鼠中潜伏期的主要部位)和CD4(+) T细胞。在OTI/B6小鼠中,OTI CD8(+) T细胞不仅降低了感染后16天从潜伏期重新激活的细胞频率和携带病毒基因组的细胞频率(与之前报道的相似),而且在感染后42天有效地降低了潜伏期。总之,这些数据表明,在没有B细胞和CD4(+) T细胞的情况下,CD8(+) T细胞足以有效控制急性复制。数据还首次证明,强烈的CD8(+) T细胞反应可以限制长期潜伏感染。